There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... it had decided to drop the twice-daily version, after seeing ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

The transition hasn't been easy. Company shares dropped again in December when Pfizer said it would abandon its twice-a-day formulation of an obesity pill due to an unacceptably high rate of side ...

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

Pfizer had scrapped the twice-daily version of its obesity pill danuglipron because most patients dropped out of the mid-stage trial with high rates of side effects such as nausea and vomiting.

That's a surprising finding: Pfizer does not have a single anti-obesity medicine on the ... Pfizer is investigating danuglipron as a twice-daily and once-daily pill, as some patients will prefer ...

How to curb and counter China’s influence and power will dominate the U.S. House’s first week back from summer break The Latest A judge says a former high-ranking Mexican official who was ...

WASHINGTON (AP) — Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. Today, CEO Albert ...